European Patent Office Grants to ASIT biotech a Second Patent Related to the Active Ingredients Used in the ASIT+™ Allergy ...
23 November 2017 - 5:00PM
Business Wire
Regulatory News:
ASIT biotech (Euronext: ASIT - BE0974289218), a Belgian
clinical-stage biopharmaceutical company focused on the research,
development and future commercialization of breakthrough
immunotherapy products for the treatment of allergies, announces
the positive decision of the European Patent Office to grant a
second patent covering an improvement to the production process of
the active ingredients used in the ASIT+™ allergy immunotherapy
products candidates for pollen, mite and food allergies (reference
EP 2 721 051 A1).
The grant will be effective from November 29, 2017 until June
15, 2032 with a possible extension of 5 years via a supplementary
protection certificate. The corresponding patent is already
granted to ASIT biotech in Australia. Patent prosecutions for the
grant in Canada, Japan, USA, China, India and Brazil are
ongoing.
Thierry LEGON, CEO of ASIT biotech, comments: “The grant of this
second patent in Europe is a new milestone in the protection of our
intellectual property. As Europe is currently the biggest market of
allergy immunotherapy products in the world, the long-term
protection conferred by this patent in Europe is of high strategic
importance.”
***
About ASIT biotech
ASIT biotech is a Belgian clinical stage biopharmaceutical
company focused on the development and future commercialisation of
a range of breakthrough immunotherapy products for the treatment of
allergies. Thanks to its innovative ASIT+™ technology platform,
ASIT biotech is currently the only developer of AIT product
candidates consisting of a unique mixture of highly purified
natural allergen fragments in an optimal size selection. This
innovation results in a short treatment, expected to improve
patient compliance and real-life effectiveness. ASIT biotech’s
product pipeline entails two novel ASIT+™ product candidates
targeting respiratory allergy with the highest prevalence (i.e.
grass pollen: gp-ASIT+™ and house dust mite: hdm-ASIT+™), that
could significantly expand the current immunotherapy market. The
Company believes that its innovative ASIT+™ platform is flexible
and would be applicable across a range of allergies.
ASIT biotech has a headcount of 22 staff members, at its
headquarters in Brussels and a laboratory in Liège, Belgium.
Further information can be found at: www.asitbiotech.com.
Forward Looking Statements
All statements in this announcement that do not relate to
historical facts and events are “forward-looking statements”. In
some cases, these forward-looking statements can be identified by
the use of forward-looking terminology, including the words
“believes,” “estimates,” “anticipates,” “expects,” “intends,”
“may,” “will,” “plans,” “continue,” “ongoing,” “potential,”
“predict,” “project,” “target,” “seek” or “should” or, in each
case, their negative or other variations or comparable terminology
or by discussions of strategies, plans, objectives, targets, goals,
future events or intentions. Forward-looking statements include
statements regarding the Company’s intentions, beliefs or current
expectations. By their nature, forward-looking statements involve
known and unknown risks and uncertainties because they relate to
events and depend on circumstances that may or may not occur in the
future. Forward-looking statements are not guarantees of future
performance. Given these risks and uncertainties, you should not
rely on forward-looking statements as a prediction of actual
results. Any forward-looking statements are made only as of the
date of this announcement and, without prejudice to the Company’s
obligations under applicable law in relation to disclosure and
ongoing information, the Company does not intend, and does not
assume any obligation, to update the forward-looking statements set
forth in this announcement.
Important Legal Notice
This announcement does not constitute, or form part of, an offer
or invitation to sell or issue, or any solicitation of an offer to
purchase or subscribe for shares of ASIT biotech SA (the “Company”
and the “Shares”). Any purchase of, subscription for or application
for, Shares to be issued in connection with the intended offering
should only be made on the basis of information contained in the
prospectus and any supplements thereto, as the case may be. This
announcement does not constitute a prospectus and the information
contained herein is for information purposes only and does not
purport to be full or complete. Investors should not subscribe for
any Shares except on the basis of the information contained in the
prospectus that the Company expects to publish after its approval
by the Belgian Financial Services and Markets Authority, and which
can then be obtained at the Company’s registered office and on
www.asitbiotech.com.
This announcement is not for distribution, directly or
indirectly, in or into the United States or to any U.S. person
within the meaning of the U.S. Securities Act of 1933, as amended
(the “Securities Act”). The Shares have not been and will not be
registered under the Securities Act and may not be offered or sold
in the United States, except pursuant to an exemption from the
registration requirements of the Securities Act. The Company has
not registered, and does not intend to register, any portion of the
intended offering of Shares in the United States, and does not
intend to conduct a public offering of Shares in the United
States.
This announcement and the information contained herein are not
for publication, distribution or release in or into the United
States, Australia, Canada, Japan or any jurisdiction where to do so
would constitute a violation of the relevant laws of such
jurisdiction.
The Company is responsible for the information contained in this
press release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171122005602/en/
ASIT biotechThierry Legon, CEO, +32 2 264 03
90investors@asitbiotech.comorMedia and Investor Relations -
FranceNewCapDusan Oresansky / Pierre Laurent, +33 1 44 71 94
92asitbiotech@newcap.euorMedia Relations - BelgiumLaure-Eve
Monfort, +32 2 290 90 93monfort@comfi.be
Aberforth Split Level In... (LSE:ASIT)
Historical Stock Chart
From Apr 2024 to May 2024
Aberforth Split Level In... (LSE:ASIT)
Historical Stock Chart
From May 2023 to May 2024